Krystal Biotech, Inc. — Director's Dealing 2021

Mar 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Krystal Biotech, Inc. (KRYS)
CIK: 0001711279
Period of Report: 2021-02-26

Reporting Person: Romano Kathryn (Chief Accounting Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-26	Common Stock	A	19600	—	Acquired	19600	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-26	Stock Option (Right to Buy)	$78.89	A	29400	Acquired	2025-02-26	Common Stock (29400)	Direct

Footnotes

F1: Award of restricted stock which vests in four equal annual installments beginning on February 26, 2022.

F2: The option vests in four equal annual installments beginning on February 26, 2022.